Overview of approved CAR-T therapies, ongoing clinical trials, and its impact on clinical practice

eJHaem

article

Salyka Sengsayadeth¹  Bipin N. Savani¹  Olalekan Oluwole¹  Bhagirathbhai Dholaria¹ 

[1] Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center

关键词: acute lymphoblastic leukemia;    CAR-T cell therapy;    diffuse large B-cell lymphoma;    multiple myeloma;    non-Hodgkin lymphoma;   

DOI  :  10.1002/jha2.338

来源: Wiley

【 摘 要 】

In recent years, we have seen rapid expansion of chimeric antigen receptor T-cell (CAR-T) therapies in multiple malignancies. CAR-T therapy has profoundly altered the treatment landscape of non-Hodgkin lymphoma, B-cell acute lymphoblastic leukemia, and multiple myeloma. Currently available CD19 and B-cell maturation antigen-directed CAR-T therapies have shown high overall response rate and durable remissions in patients who have failed standard therapies. Multiple studies are underway exploring the role of CAR-T-cell therapy as earlier line of treatment. In high-grade B-cell lymphoma, CD19 CAR-T therapy may replace autologous hematopoietic cell transplantation as second line therapy in near future. CAR-T-cell therapy targeting novel tumor-associated antigens will help expand utility of this treatment modality in other hematological malignancies. It may also help overcome limitations of currently approved CAR-T-cell therapies. In this review, we have provided an overview of currently approved CAR-T therapies and upcoming clinical trials which may potentially impact the clinical practice.

【 授权许可】

Unknown